AMAL aims to tackle the obstacles for effective anti-cancer therapy by stimulating a patient’s immune system in a unique way.
KISIMA®, our unique proprietary protein-based immunisation platform is self-adjuvanting and delivers several antigens in one single vaccine.
We focus on the development of viable effective cancer therapies. Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of metastatic colorectal cancers.
Our strategy is to develop KISIMA® and its current indications in oncology through to phase II, in-house or through strategic partnerships.
November 6 – 10, 2019 / Washington / USA
Marie-Laure Santiago-Raber attending
November 11–13, 2019 / Hamburg / Germany
Laurence de Schoulepnikoff attending
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
Website by Instinctif Partners